Aurora-BioPharma,-inc.-logo

Aurora BioPharma, inc.

Aurora BioPharma is a biotechnology company based in Cambridge, Massachusetts commercializing cutting-edge cancer adoptive cell immunotherapy. Aurora Bioparma is developing Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Auroras platform targets main and co-stimulatory solid tumor associated antigens present on a range of solid tumor cancers, starting with brain tumors, sarcomas, and breast cancers.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.aurora-biopharma.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Harvard Square One Mifflin Place, Suite 400, MA 02138
Cambridge
United States
Email
Contact Number
+1617 674-7718

Aurora Bioparma is developing Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Auroras platform targets main and co-stimulatory solid tumor associated antigens present on a range of solid tumor cancers, starting with brain tumors, sarcomas, and breast cancers.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Aurora is developing genetic approaches to reprogram T cells with Bi-Specific CAR T Cells that target main and co-stimulatory solid tumor associated antigens present on a broad range of solid tumor cancers, starting with Brain tumors, Sarcomas, and Breast cancers.

AU101 uses a chimeric receptor made from an antibody that recognizes HER2 positive cells that is then expressed in T cells to kill cancer cells that are HER2 positive. The CAR also contains another component called CD28 that should enable the cells to last longer in the body and therefore be more effective.